| Vero Health & Rehab Of Hampden | |
| 34 Main Street, Hampden, Massachusetts 01036 | |
| (413) 566-5511 | |
| Name | Vero Health & Rehab Of Hampden |
|---|---|
| Location | 34 Main Street, Hampden, Massachusetts |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 100 |
| Occupancy Rate | 89.2% |
| Medicare ID (CCN) | 225265 |
| Legal Business Name | Vero Health Xi Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1003867532 |
| Organization Name | SRC HAMPDEN, INC. |
| Doing Business As | WINGATE AT HAMPDEN REHAB. & SKILLED NSG. RESIDENCE |
| Address | 34 Main St, Hampden, MA 01036 |
| Phone Number | 413-566-5511 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
A new study by researchers at the Bradley Hasbro Children's Research Center and the University of Puerto Rico may help explain some of the well-documented ethnic disparities in pediatric asthma.
In a groundbreaking study that offers new hope for women with advanced breast cancer, researchers from UCLA's Jonsson Comprehensive Cancer Center have published final clinical trial results that showed the amount of time patients were on treatment without their cancer worsening (called progression-free survival) was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.
Although treatment advances have dramatically reduced deaths from opportunistic infections related to AIDS, a new study drawing on 30 years of data from more than 20,000 patients in San Francisco suggests there is still ample room to improve. About a third-35 percent-of AIDS patients diagnosed with their first opportunistic infection from 1997 to 2012 in that city died within five years, according to the study, published in the Journal of Infectious Diseases.
› Verified 3 days ago
| NPI Number | 1659832236 |
| Organization Name | VERO HEALTH XI, LLC |
| Doing Business As | VERO HEALTH & REHAB OF HAMPDEN |
| Address | 34 Main St, Hampden, MA 01036 |
| Phone Number | 413-566-5511 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
A new study by researchers at the Bradley Hasbro Children's Research Center and the University of Puerto Rico may help explain some of the well-documented ethnic disparities in pediatric asthma.
In a groundbreaking study that offers new hope for women with advanced breast cancer, researchers from UCLA's Jonsson Comprehensive Cancer Center have published final clinical trial results that showed the amount of time patients were on treatment without their cancer worsening (called progression-free survival) was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.
Although treatment advances have dramatically reduced deaths from opportunistic infections related to AIDS, a new study drawing on 30 years of data from more than 20,000 patients in San Francisco suggests there is still ample room to improve. About a third-35 percent-of AIDS patients diagnosed with their first opportunistic infection from 1997 to 2012 in that city died within five years, according to the study, published in the Journal of Infectious Diseases.
› Verified 3 days ago
| NPI Number | 1720749468 |
| Organization Name | VANTAGE AT HAMPDEN LLC |
| Address | 34 Main St, Hampden, MA 01036 |
| Phone Number | 413-566-5511 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
A new study by researchers at the Bradley Hasbro Children's Research Center and the University of Puerto Rico may help explain some of the well-documented ethnic disparities in pediatric asthma.
In a groundbreaking study that offers new hope for women with advanced breast cancer, researchers from UCLA's Jonsson Comprehensive Cancer Center have published final clinical trial results that showed the amount of time patients were on treatment without their cancer worsening (called progression-free survival) was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.
Although treatment advances have dramatically reduced deaths from opportunistic infections related to AIDS, a new study drawing on 30 years of data from more than 20,000 patients in San Francisco suggests there is still ample room to improve. About a third-35 percent-of AIDS patients diagnosed with their first opportunistic infection from 1997 to 2012 in that city died within five years, according to the study, published in the Journal of Infectious Diseases.
› Verified 3 days ago
| NPI Number | 1790775336 |
| Organization Name | MARY LYON NURSING AND REHABILITATION CENTER |
| Doing Business As | RADIUS 91 LYONS OPERATING, LLC |
| Address | 34 Main St, Hampden, MA 01036 |
| Phone Number | 413-566-5511 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
A new study by researchers at the Bradley Hasbro Children's Research Center and the University of Puerto Rico may help explain some of the well-documented ethnic disparities in pediatric asthma.
In a groundbreaking study that offers new hope for women with advanced breast cancer, researchers from UCLA's Jonsson Comprehensive Cancer Center have published final clinical trial results that showed the amount of time patients were on treatment without their cancer worsening (called progression-free survival) was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.
Although treatment advances have dramatically reduced deaths from opportunistic infections related to AIDS, a new study drawing on 30 years of data from more than 20,000 patients in San Francisco suggests there is still ample room to improve. About a third-35 percent-of AIDS patients diagnosed with their first opportunistic infection from 1997 to 2012 in that city died within five years, according to the study, published in the Journal of Infectious Diseases.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
A new study by researchers at the Bradley Hasbro Children's Research Center and the University of Puerto Rico may help explain some of the well-documented ethnic disparities in pediatric asthma.
In a groundbreaking study that offers new hope for women with advanced breast cancer, researchers from UCLA's Jonsson Comprehensive Cancer Center have published final clinical trial results that showed the amount of time patients were on treatment without their cancer worsening (called progression-free survival) was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.
Although treatment advances have dramatically reduced deaths from opportunistic infections related to AIDS, a new study drawing on 30 years of data from more than 20,000 patients in San Francisco suggests there is still ample room to improve. About a third-35 percent-of AIDS patients diagnosed with their first opportunistic infection from 1997 to 2012 in that city died within five years, according to the study, published in the Journal of Infectious Diseases.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $20000 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 27.59 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 11.93 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 51.85 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.03 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.3 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.38 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.69 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 80.2 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 41.78 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 36.32 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 15 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 35.89 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 31.79 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.24 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 91.38 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 54.08 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 53.94 | 82.93 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.
A new study by researchers at the Bradley Hasbro Children's Research Center and the University of Puerto Rico may help explain some of the well-documented ethnic disparities in pediatric asthma.
In a groundbreaking study that offers new hope for women with advanced breast cancer, researchers from UCLA's Jonsson Comprehensive Cancer Center have published final clinical trial results that showed the amount of time patients were on treatment without their cancer worsening (called progression-free survival) was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.
Although treatment advances have dramatically reduced deaths from opportunistic infections related to AIDS, a new study drawing on 30 years of data from more than 20,000 patients in San Francisco suggests there is still ample room to improve. About a third-35 percent-of AIDS patients diagnosed with their first opportunistic infection from 1997 to 2012 in that city died within five years, according to the study, published in the Journal of Infectious Diseases.
› Verified 3 days ago
Vero Health & Rehab Of Hampden Location: 34 Main Street, Hampden, Massachusetts 01036 Phone: (413) 566-5511 |